Halcyon Molecular

Halcyon Molecular was an American company that tried to read the sequence of DNA by photographing single molecules in an electron microscope. Based in Redwood City, California, it labeled the bases of DNA with heavy metal atoms, laid long strands out straight on films a few nanometers thick and planned to read the order of the labels from images taken with a scanning transmission electron microscope. In 2009 it described its goal as sequencing a complete human genome in less than ten minutes for less than $100. It released no product and closed in 2012.

Kent Kemmish, later the founder of Molecular Reality Corporation, was on its founding team from 2009 to 2012. He wrote the winning application for a 2009 grant from the National Human Genome Research Institute made jointly with the laboratory of George Church at Harvard Medical School, and worked on the company's method for stretching and placing DNA, Molecular Threading. The company's sequencing method outlived it as a paragraph in other companies' patents, where it was still being reprinted in 2026.

The idea of reading DNA in an electron microscope is older than DNA sequencing. A 1959 lecture at Caltech, There's Plenty of Room at the Bottom, proposed improving the microscope until biologists could simply look at the order of the bases, and a paper of 1962 in the Proceedings of the National Academy of Sciences studied whether a marker attached to one kind of base could be seen.^[8] The difficulty is contrast. The bases are built from carbon, nitrogen, oxygen and hydrogen, light atoms that scatter electrons weakly and look alike, and the beam that images them also damages them. Heavy atoms scatter far more strongly. A scanning transmission electron microscope that collects electrons scattered to high angles, the annular dark-field method, made single heavy atoms visible in 1970.^[9] Halcyon was one of two companies pursuing the approach in the late 2000s. The other, ZS Genetics of Connecticut, proposed labeling three of the four bases with bromine, iodine and a third heavy group, and in 2012 its collaborators reported identifying labeled bases in electron micrographs.^[10]

The attraction was length. In 2009 the instruments that produced most of the world's DNA sequence read fragments of a few hundred bases or fewer, and a genome had to be assembled from millions of overlapping pieces. A single strand imaged whole could, in principle, be read across hundreds of thousands of bases, carrying with it the long-range order that short fragments lose, such as which of two copies of a chromosome a variant sits on.

Halcyon's plan combined these pieces. Each kind of base would carry its own heavy-atom label, the labeled single strands would be stretched straight on a thin film, and the microscope would record where each label sat along the strand. GenomeWeb described the method as labeling the molecule "with base-specific heavy metal atoms" and imaging it with a scanning transmission electron microscope to read the sequence "with single-base resolution".^[1] The labels the company worked with included osmium tetroxide 2,2'-bipyridine, which attaches to thymidine; it appears as an "EM-dense" contrast agent in the company's published images.^[6]

Straight, evenly spaced DNA was as necessary as the labels. Molecular Threading pulled DNA out of a droplet with a glass micro-needle and laid it on films of silicon or silicon nitride 5 nm thick, in parallel rows. In the company's electron micrographs, threaded strands strayed sideways by less than 10 nm over more than a micrometer of length; its sharpest images came from a Nion UltraSTEM 100, a microscope with a resolution of about 0.1 nm.^[6]

The patents of other companies give the fullest description of the plan, under a name it acquired there:

The method, termed Individual Molecule Placement Rapid Nano Transfer (IMPRNT), comprises utilizing single atom resolution transmission electron microscope imaging of high-molecular weight (150 kb or greater) DNA selectively labeled with heavy atom markers and arranging these molecules on ultra-thin films in ultra-dense (3 nm strand-to-strand) parallel arrays with consistent base-to-base spacing.

US Patent 10,662,474 B2 (2020)

The same paragraph ends: "The method allows for sequencing complete human genomes in less than ten minutes."^[11]

The IMPRNT paragraph entered the boilerplate of patents on prenatal testing, where applicants list every DNA sequencing technology their claims might cover. A search of Google Patents in October 2026 found the phrase "Individual Molecule Placement Rapid Nano Transfer" in 123 patent documents published between July 2012 and July 2026, most of them filed by Verinata Health, Sequenom and Illumina, companies that developed tests reading fetal DNA in the mother's blood.^[12] The patent quoted above was granted on May 26, 2020, eight years after the company closed. The most recent document in the search was published on July 16, 2026, and concerns detecting ovarian cancer.^[12]

Kemmish dates his idea for a mechanical nanopore, a hole whose size could be changed by sliding one membrane across another, to 2012, the year his time at Halcyon ended. In 2018 he became a founder of demonpore, inc., the company that was renamed Molecular Reality Corporation in 2021.^[13] George Church became the first formal member of its scientific advisory board.^[13] Kemmish's own patent on sliding occlusion, granted in 2021, lapsed in 2025 for the same reason as Halcyon's, an unpaid maintenance fee.^[14]

• History of nanopore sequencing
• Nanopore sequencing
• DNA